LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer's Disease

Eisai Co., Ltd. and Biogen Inc. have announced the approval of LEQEMBI® Pen, a subcutaneous (SC) formulation of the anti-amyloid beta (Aβ) protofibril antibody LEQEMBI (lecanemab), in Japan. This new autoinjector allows for once-weekly at-home administration by a care partner or patient, offering a more convenient alternative to the bi-weekly intravenous infusions in a hospital setting. The approval is expected to reduce the burden of clinic visits and streamline the Alzheimer's disease treatment pathway.